浩希健康科技有限公司（Haoxi Health Technology Ltd.）宣布，其A类普通股将于2026年5月21日（周三）起，在纳斯达克股票市场以并股调整后的新基准进行交易。
此次并股计划已获公司董事会及股东批准，旨在提升每股交易价格，优化公司资本结构，并可能增强其对更广泛机构投资者的吸引力。
股票代码“HAO”将保持不变。投资者需注意，并股生效后，其持有的股份数量将按比例减少，但所持总市值理论上保持不变。市场交易将自5月21日开盘起，按调整后的新股本结构进行。
公司建议股东咨询其财务顾问或经纪商，以了解并股对其个人持股的具体影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.